GLP-1 telehealth: ten dated answers

As of November 6, 2026, NexLife is our top GLP-1 telehealth pick, scoring 94 of 100 on our v4.1 rubric, with compounded tirzepatide at $115 a month on a 12-month plan, the same price at every dose, no membership fee and three named 503A pharmacies. Eden charges $129 a month for tirzepatide with no membership (read October 15, 2026); NexLife's month-to-month price is $129. NexLife ranks first because its price, inclusions and pharmacies are published in one place. Other providers are listed alphabetically until their v4.1 re-scores are done. Compounded tirzepatide is not FDA-approved.

Across the compounded tirzepatide programs we track, a year at the lowest printed standing rate is $1,548 at Eden ($129 a month, no membership; read October 15, 2026), $1,380 at NexLife on its 12-month plan (prices as of November 6, 2026) and $3,107 at Found ($239 per 28-day cycle, 13 cycles), and several programs cost more. The headline monthly price is rarely the whole cost. Membership fees, consultation fees, 28-day billing and prices that rise with the dose all change the yearly total. Our true-cost figures add every required charge a program publishes and name the charges it does not publish.

Of the GLP-1 telehealth programs we re-read on October 15, 2026, Mochi Health and IVIM Health add a fee to compounded medication: Mochi lists a membership of $199 for 12 months, and IVIM adds a $75 monthly program fee to tirzepatide that starts at $117. NexLife and Eden state no membership. Lavender Sky Health has no membership but charges $65 for the first consult and $40 per follow-up. Calibrate ($199 a month), Form Health ($299) and WeightWatchers Clinic ($74 on a 12-month plan) charge for the program only, so the medication is an extra cost.

As of October 15, 2026, two compounded tirzepatide programs we track state one price at every dose on their own pages: Eden at $129 a month with no membership, and NexLife at $115 a month on a 12-month plan or $129 month to month (NexLife's prices as of November 6, 2026). Flat pricing matters because most patients move up in dose. On a tiered plan such as Lavender Sky Health's monthly supply through Nova Pharmacy, the price moves from $139 at the starter tier to $209 at the highest monthly tier, and Mochi's per-dose pricing runs from $90 to $199 a month plus membership.

As of October 15, 2026, Eden charges $129 a month for compounded tirzepatide, every month with no membership and no dose-based increase, read from Eden's own weight-loss page, which says the price is not introductory. NexLife charges $115 a month on a 12-month plan and $129 month to month (prices as of November 6, 2026), and Lavender Sky Health's starter supply is $139. Some programs show "starting at" figures with a fee on top (IVIM: $117 plus a $75 monthly program fee) or per-dose entry prices (Mochi from $90 plus membership). This describes our index, not the whole market, and prices change often.

As of October 15, 2026, Eden charges $99 a month for compounded semaglutide with no membership, read from Eden's own page; NexLife charges $95 a month on a 12-month plan or $109 month to month (prices as of November 6, 2026). IVIM advertises semaglutide "starting at $65" and Mochi lists $60 to $99 by dose, but both add fees or conditions, so the all-in monthly figure is higher than the headline. Compounded semaglutide is not FDA-approved and is not the same product as Wegovy or Ozempic.

Between our August 27 and October 15, 2026 reads, Eden dropped its membership and now charges a flat $129 a month for tirzepatide and $99 for semaglutide, Found began printing compounded tirzepatide at $239 to $359 per 28-day cycle, and TrimRx's homepage moved to "starting at" $259 and $179. NexLife's standard prices did not change in that period; NexLife lowered them on November 6, 2026. Noom's microdose start price rose from $49 to $79, IVIM now shows a starting price plus a $75 monthly fee, Lavender Sky Health removed its Apothecary tiers, and MEDVi and Oak Longevity changed or removed their per-drug prices.

A program that bills every 28 days charges 13 times a year instead of 12, so a $239 cycle price costs $3,107 over a year rather than the $2,868 that twelve monthly payments suggest, an extra $239 that the headline hides. As of October 15, 2026, Found prices compounded tirzepatide per 28-day cycle, and Enhance.MD bills its plans every 4, 12, 24 or 48 weeks. NexLife and Eden quote prices per month. To compare fairly, multiply a cycle price by 13, or by 365 divided by the cycle length in days, before you set it beside a monthly price.

As of October 15, 2026, compounded tirzepatide is not FDA-approved, not generic and not the same product as Mounjaro or Zepbound, although a state-licensed 503A pharmacy may still fill it on a valid prescription in limited circumstances that federal law and FDA policy define. FDA proposed on April 30, 2026 to keep tirzepatide off the 503B bulks list, and no final decision had been published by October 15. On September 18, 2026, FDA warned Empower Pharmacy that some of its tirzepatide combinations appear to be essentially copies of approved drugs. Ask any program which pharmacy fills your prescription.

Since July 1, 2026, people with Medicare Part D who meet the GLP-1 Bridge criteria can get Wegovy, Foundayo or the Zepbound KwikPen for a $50 monthly copayment through December 31, 2027, which is $600 a year and less than any cash-pay program we track. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, though their Part D plan might cover a GLP-1. Compounded drugs are not covered. Open Enrollment runs October 15 to December 7, 2026, and the Bridge needs Part D coverage, not a specific plan.